Title
Bristol-Myers Squibb CA047004 (Phase 1 NKG2A inhibitor- Head and Neck)
Study Title
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors
Malignancy
Head and neck cancer (SCCHN), laryngeal, hypopharyngeal, oropharyngeal, oral cavity, oropharynx, hypopharynx, larynx
Investigational Agent
BMS-986315 with either nivolumab or cetuximab
Key Eligibility Criteria Details
- SCCHN
- Must have received prior PD-1 or PD-L1 inhibitor
- ECOG PS 0-1
- No known autoimmune disease
- No need for steroids or other immunsuppressive medicine
- No interstitual lung disease or pulmonary fibrosis